Join us on Saturday, January 23rd, 2021, at 12:00 pm EST for a webinar featuring a discussion of how gene therapies can be used to address retinal degenerative diseases, as well as the latest updates on gene therapy research and clinical trials.
Acquisition significantly expands Janssen’s eye disease portfolio and strengthens its gene therapy capabilities. Late-stage AMD affects millions of people with no effective treatments currently available .
ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA therapies for severe genetic rare diseases, today announced virtual presentations at the Ophthalmology Futures Retina Forum, European Society of Retina Specialists (Euretina) congress and the Annual Meeting of the American Academy of Optometry (AAOpt).
Dr. Jacque Duncan, UCSF Professor of Clinical Ophthalmology, is currently working on therapies restoring vision for retinal degenerative diseases. Dr. Duncan has hope and optimism for the future that vision will be restored for those with retinal diseases, thanks in part by the Foundation’s work.
The urgent mission of the Foundation Fighting Blindness is to drive the research that will provide preventions, treatments and cures for people affected by retinitis pigmentosa, macular degeneration, Usher syndrome and the entire spectrum of retinal degenerative diseases. The Foundation is a beacon for those affected by these blinding diseases. Join the fight and help us accelerate our mission.
Welcome to the Foundation site — supported in partnership with Genentech, A Member of the Roche Group.